WHO recommends GenoType MTBDRsl VER 2.0

WHO recommends GenoType MTBDRsl as first and only rapid test for detection of additional resistance in MDR-TB patients as well as XDR-TB. The test system is recommended for patients with confirmed rifampicin-resistant TB or MDR-TB as the initial test to detect resistance to fluoroquinolones and the second-line injectable drugs, instead of phenotypic culture-based drug-susceptibility testing (DST).
Thus, step-wise diagnostics for MDR- and XDR-TB with GenoType MTBDRplus VER 2.0 and GenoType MTBDRsl VER 2.0 is possible!

Further information:












Click on the picture for further information about the Recommendation

Click here for WHO webpage 

Clicke here for further information about GenoType MTBDRsl VER 2.0